Abstract
Sodium glucose cotransporter 2 (SGLT2) inhibition is a novel and promising treatment for diabetes under late-stage clinical development. It generally is accepted that SGLT2 mediates 90% of renal glucose reabsorption. However, SGLT2 inhibitors in clinical development inhibit only 30-50% of the filtered glucose load. Why are they unable to inhibit 90% of glucose reabsorption in humans? We will try to provide an explanation to this puzzle in this perspective analysis of the unique pharmacokinetic and pharmacodynamic profiles of SGLT2 inhibitors in clinical trials and examine possible mechanisms and molecular properties that may be responsible.
Original language | English (US) |
---|---|
Pages (from-to) | 2199-2204 |
Number of pages | 6 |
Journal | Diabetes |
Volume | 61 |
Issue number | 9 |
DOIs | |
State | Published - Sep 2012 |
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism